Highlights

  • PermeaDerm achieved a mean treatment cost of $148.70 per 1% TBSA versus $497.10 for allograft — a 70% cost advantage, statistically significant at p<0.001.
  • Preparation time was reduced by 95.7% compared with cadaveric allograft.
  • About 94% of PermeaDerm patients achieved at least 95% graft take one week after autografting, comparable to allograft.
  • The randomised controlled trial enrolled 40 patients across 11 US burn centres, with no adverse events attributed to PermeaDerm.

AVITA Medical (ASX:AVH) shares jumped sharply to $2.71 on 19 August 2026, recording a gain of 23.18%, after the medical device company announced positive clinical trial results demonstrating its PermeaDerm biosynthetic wound matrix delivers a 70% cost advantage over traditional cadaveric allograft. The PermeaDerm-I study compared AVITA's biosynthetic product directly against allograft — the current standard of care for temporary wound coverage following surgical excision — and found clear economic and operational advantages.

The Cost Advantage

On cost, the study's primary endpoint, PermeaDerm achieved a mean treatment cost of $148.70 per 1% of total body surface area (TBSA) treated, compared with $497.10 for allograft. That represents a saving of approximately $348 per percentage point of TBSA and a 70% lower product cost, with the result statistically significant at p<0.001 — a compelling economic argument for hospital procurement teams.

Operational Advantages Beyond Cost

PermeaDerm also demonstrated significant operational benefits. Preparation time was reduced by 95.7% compared with allograft, since the product does not require the tissue tracking, thawing or meshing procedures associated with cadaveric tissue. Its off-the-shelf format eliminates these workflow burdens, and its transparent bilayer structure allows clinicians to visualise the wound bed without removing the matrix.

Clinical Outcomes Comparable to Allograft

The randomised controlled study enrolled 40 patients across 11 US burn centres with eligible wounds involving up to 30% TBSA. Approximately 94% of patients treated with PermeaDerm achieved at least 95% graft take one week after autografting — comparable with allograft outcomes. At eight weeks, all patients in both treatment groups achieved at least 95% wound healing. No adverse events were attributed to PermeaDerm, and both investigators and patients reported being satisfied or very satisfied with the treatment experience.

The trial design was comprehensive: PermeaDerm-I was a post-market, multicentre randomised controlled trial with patients followed for eight weeks after definitive closure, assessing preparation time, application time, graft take, wound healing, inflammatory response, adverse events, and surgeon and patient satisfaction.

Part of a Broader Wound Care Portfolio

PermeaDerm sits within AVITA's broader acute wound care portfolio, alongside RECELL — a spray-on skin technology using the patient's own skin — and Cohealyx, a collagen-based dermal matrix. AVITA holds exclusive US rights to manufacture, market, sell and distribute PermeaDerm.

What the Data Doesn't Yet Say

Investors should note two caveats. First, AVITA has not stated that the cost figures represent a direct reduction in total hospital treatment costs — the analysis is focused specifically on product cost per percentage of TBSA treated. Second, the company did not indicate whether these results will translate into near-term Revenue or Earnings impact, with the announcement centred on clinical and economic data rather than a commercialisation timeline.

Conclusion

In a US burn care market where length of hospital stay and preparation time are critical cost drivers, a product delivering equivalent clinical outcomes at 70% lower product cost and minimal preparation time addresses a genuine procurement pain point. That potential — rather than any confirmed near-term earnings impact — appears to be what is driving today's strong investor reaction.